Bristol-myers Squibb Compnay

Boehringer Ingelheim International Gmbh

Gilead Sciences, Inc.

Carl Thibeault

Jennifer X Qiao

Patrick Y S Lam

Lee Fader

Tammy C Wang

Rejean Ruel

Alexandre L'Heureux

Simon Surprenant

Francois Bilodeau

Murray D Bailey

Charles G Clark

Carol Hui Hu

Rebekah J Carson

Mathieu Parisien

Wu Yang

Pierre Louis Beaulieu

Christiane Yoakim

Youla S Tsantrizos

James Clifford Sutton

Bruno Simoneau

Yufeng Wang

Jacques Y Roberge

Zulan Pi

Timur Gungor

Timothy F Herpin

Hannguang J Chao

Stephen Kawai

Robert P Rehfuss

Sebastien Morin

Maude A Poirier

Cyrille Kuhn

Huji Tuerdi

Gilles Bouthillier

Yalei Liu

Dora M Schnur

Steven R Laplante

R Michael Lawrence

John E Lloyd

Jean Rancourt

Martin Duplessis

Clint A James

Yoon T Jeon

Cédrickx Godbout

George O Tora

James Gillard

Elisia Villemure

Benoît Moreau

Michael S Bowsher

Martin Poirier

Chantal Grand-Maitre

Melissa Leblanc

Eric Jolicoeur

Julie Naud

Oliver Hucke

Jean-Eric Lacoste

Sheldon Hiebert

Louis Morency

Indawati DeLucca

Michael R Lawrence

André Giroux

Sébastien Morin

Olivier Lepage

Thao Trinh

Anne Décor

François Bilodeau

Ruel Rejean

Alexandre L L'HEUREUX

Jacques Yves Roberge

Timothy Herpin

Pierre L Beaulieu

Anne DÉCOR

Maude Poirier

Patrick YS Lam

Benoit Moreau

Rebekah Carson

Murray Bailey

The present invention provides compounds of Formula (I): Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Yreceptor which may be used medicaments. 

[object Object]

Compounds of Formula (I) wherein R, R, R, R, Y, Zand Zare defined herein, are useful for the treatment of cytomegalovirus disease and/or infection. 

Inhibitors of cytomegalovirus

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Yreceptor and may be used as medicaments in the treatment and/or prophylaxis of thromboembolic disorders. 

Compounds of Formula (I) wherein n, R, R, R, Rand Z are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection. 

Compounds of Formula (I) wherein n, m, R, R, R, R, R5 and R6 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection. 

Cytomegalovirus inhibitor compounds

Compounds of Formula (I) wherein n, R, R, R, R, Y and Z are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Yreceptor which may be used as medicaments. 

Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of P2Y1 receptor

Compounds of formula I: wherein a, R, R, R, R, Rand Rare defined herein, are useful as inhibitors of HIV replication.

Inhibitors of human immunodeficiency virus replication

The present invention provides novel heteroaryl compounds and analogues thereof, which are selective inhibitors of the human P2Yreceptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Yreceptor activity.

The present invention provides novel C-linked cyclic compounds and analogues of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, D and W are as defined herein. These compounds are selective inhibitors of the human P2Yreceptor which can be used as medicaments.

The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Yreceptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Yreceptor activity.

Growing community of inventors

Mascouche, Canada

Carl Thibeault